Alnylam Pharmaceuticals Company Insiders

Alnylam Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.0292) % which means that it has lost $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0066) %, meaning that it created substantial loss on money invested by shareholders. Alnylam Pharmaceuticals' management efficiency ratios could be used to measure how well Alnylam Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 2.10 in 2024, whereas Return On Tangible Assets are likely to drop (0.15) in 2024. At this time, Alnylam Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 889.5 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (547.6 M). Common Stock Shares Outstanding is likely to drop to about 70.4 M in 2024. Net Loss is likely to rise to about (967.1 M) in 2024

Alnylam Pharmaceuticals Workforce Comparison

Alnylam Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (0.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.

Alnylam Pharmaceuticals Insider Trading History

Alnylam Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Alnylam Pharmaceuticals often depends on how effective the management is. Alnylam Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alnylam management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alnylam management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Alnylam Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alnylam Pharmaceuticals. Check Alnylam Pharmaceuticals' Beneish M Score to see the likelihood of Alnylam Pharmaceuticals' management manipulating its earnings.

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.